
Rare Disease Day 2024 at NIH was held on Thursday, February 29, and it was a profoundly moving event attended by 100s in person and over 500 via webcast. There are approximately 10,000 known rare diseases and treatments for only 500. Further, despite each disease being rare on its own, it is estimated that, cumulatively, over 400 million people globally suffer from a rare disease. A rare disease is defined as one that affects fewer than 200,000 people. In addition to numerous plenary presentations, the NIH event featured over 100 posters and exhibits, as well as an art display titled “Beyond the Diagnosis” and films.
Individual Rare Disease Day events are held around the country and the world at the end of February to raise awareness of the need for progress in the illumination and treatment of these diseases and to bring hope to the families that are struggling with a rare disease.
Often families endure a long and frustrating odyssey of countless physician visits to even arrive at the correct diagnosis of a rare disease. And then there often is no treatment. It is a grim ordeal for parents who are seeking help for their beloved children (an estimated 70% of rare diseases are first seen in children). But with rapidly advancing research there comes ever more hope. And this can be seen in the FDA’s 2023 approval of multiple drugs/gene therapies for rare diseases, including vamorolone for Duchenne muscular dystrophy, trofinetide for Rett syndrome, and two gene therapies for sickle cell disease.
The audience at the NIH’s Rare Disease Day included patients, families, patient advocates, physicians, scientists, and industry, and attendees were rewarded with an outstanding program of speakers that included new NIH Director Monica M. Bertagnolli, MD, and the four Co-Chairs of the US Congressional Caucus on Rare Diseases: Senator Amy Klobuchar (D-MN), Senator Roger F. Wicker (R-MS), Rep. Doris O. Matsui (D-CA), and Rep. Gus M. Bilirakis (R-FL), who made their supportive remarks via video.
The day kicked off with opening remarks by Joni Rutter, PhD, Director of the NIH’s National Center for Advancing Translational Sciences (NCATS), and James Gilman, MD, CEO of the Clinical Center at NIH. Dr. Rutter noted that a White House dinner event on Wednesday night helped to highlight the national commitment to rare diseases. She emphasized how the FDA approval of vamorolone for DMD signaled new hope for other rare conditions. She also noted the lack of animal models and the advance of chip technology to provide in silico models for disease study. Data science is advancing at a staggering and impressive pace that could accelerate rare disease research, Dr. Rutter averred. Dr. Gilman focused on the dire need for development of more treatments for the ~9,500 known rare diseases for which there is no treatment now.
Congressional Comments
These opening remarks were followed by the video addresses of the four Congressional Caucus Co-Chairs. Senator Klobuchar said that we must fight to end rare diseases and there is a great need for Federal dollars to go into research in this area. She noted that strides have been made in newborn screening and more work in this area is vital, as an estimated 70% of rare diseases begin in childhood, as noted earlier. And the earlier the diagnosis, the sooner any available treatment can begin. Representative Bilirakas emphasized the need for additional funding for first-in-kind breakthrough treatments.
A Mother’s Work
After the Congressional videos, a moving address was delivered by Dominique Pichard, MD, new Director of the Division of Rare Diseases Research Innovation (DRDRI), NCATS, NIH. In this capacity, she also collaborates with other divisions and offices across NCATS and, more broadly, with other NIH institutes and centers regarding rare diseases research. Before joining NCATS in September 2023, Dr. Pichard was the Chief Science Officer at the International Rett Syndrome Foundation — the largest patient advocacy and research foundation for Rett syndrome in the United States. Rett syndrome is a rare genetic neurological disorder that affects 1 in 10,000 females (and even fewer males) and leads to severe impairments affecting nearly every aspect of life, including speaking, walking, eating, and the ability to breathe easily. In her capacity at the International Rett Syndrome Foundation, Dr. Pichard engaged in patient advocacy and created several initiatives to improve translational research in Rett syndrome, providing the grounds for successful drug development.
In addition to her work in rare disease research, Dr. Pichard is mother to a daughter who lives with Rett syndrome, so she has a deep understanding of the many challenges associated with having a rare disease, including the diagnostic odyssey, the lack of treatments, and the many untreated medical complications related to the disease. Dr. Pichard noted positively that the FDA approved the first treatment [Daybue (trofinetide)] for Rett syndrome in 2023.
She is passionate about improving the system for all those affected by rare diseases, which aligns with NCATS’ vision of bringing more treatments to all people more quickly, and added that “rare disease has a home at NCATS.”
In closing, she noted that there is an important public workshop coming up on May 13 on “Natural History Studies and Registries in the Development of Rare Disease Treatments,” to be held at the FDA’s White Oak Campus in Silver Spring, MD.
Rare Disease Stories #1 & #2
In Rare Disease Story #1, Seema R. Lalani, MD, Professor, Department of Molecular and Human Genetics, Baylor College of Medicine, spoke on “Shortening the Diagnostic Odyssey—Project GIVE (Genetic Inclusion by Virtual Evaluation) for the Rio Grande Valley. Dr. Lalani described her work with mostly Hispanic patients in a poor section of south Texas.
In Rare Disease Story #2, Jessica Swanson titled her talk “A Typical Normal—Finding Our Stride Through Exceptional Times.” She described herself as a Rare Disease Caregiver; and Co-Chair, Undiagnosed Diseases Network Participant Engagement and Empowerment. She is also the mother of a young girl who endured a 9-year odyssey of physician visits before learning the rare disease that she was born with, namely a defect in the CDKL5 gene.
Tribute to Joni Rutter & NCATS
After Swanson, a young man withjuvenile myositis came briefly to the podium to express his thanks to Dr. Joni Rutter and the NCATS for all they had done in efforts to resolve rare diseases. He mentioned that the Cure JM Foundation web site could be visited for more information on this rare disease. The following information is from the web site: “Juvenile myositis is a rare autoimmune disease in which the body’s immune system attacks its own cells and tissues. Your doctor may refer to juvenile myositis as juvenile dermatomyositis or JDM. Juvenile dermatomyositis is the most common form of the disease. Juvenile myositis affects each child differently as the immune system typically attacks muscle and skin, resulting in significant and sometimes severe weakness and persistent rash. The exact cause of JM is unknown. Current treatments are imperfect, yet most children diagnosed today go on to live their best lives. Our work is to help make the road to their best life easier, so they can get back to being kids again faster.”
NIH Director Addresses Attendees; From Wyoming Cattle Ranch to NIH
Following a brief break, Dr. Monica Bertagnolli, the new Director of the NIH, came forward to address the audience. As an interesting sidebar, it was noted in her introduction that Dr. Bertagnolli grew up on a cattle ranch in southwest Wyoming. Her parents were first-generation French Basque and Italian immigrants. Shereceived her BS from Princeton and her MD from the University of Utah. She previously served as the 16th director of the National Cancer Institute (NCI). Prior to her governmental positions, she worked at Brigham and Women’s Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School. She began her remarks by saying that she had long been involved in the treatment of rare diseases, and had focused significantly on familial adenomatous polyposis (FAP), a rare inherited disease that often goes on to cancer.
She said she is committed to take on rare diseases and suggested the importance of gathering as much EHR data as possible with an agreement to reconnect if any relevant information is developed.
Dr. Bertagnolli highlighted the Bespoke Gene Therapy Consortium (BGTC) as a key player in the rare disease effort. The BGTC has been developed in the Accelerating Medicines Partnership® (AMP®) program, which is a public-private partnership between the NIH, the FDA, and multiple public and private organizations. Managed through the Foundation for the NIH (FNIH), the AMP program aims to improve our understanding of therapeutically relevant biological pathways and to validate information that could be relevant for the development of multiple therapeutics.
The BGTC aims to develop platforms and standards that will speed the development and delivery of customized or “bespoke” gene therapies that could treat the millions of people affected by rare diseases. Launched in October 2021, BGTC is the first AMP initiative focused on rare diseases and the sixth AMP initiative overall. The effort aims to overcome major obstacles related to developing gene therapies and will create a gene therapy protocol book that the research community can use to make the process of developing gene therapies for rare conditions much more efficient.
Dr. Bertagnolli noted that equity is a theme for Rare Disease Day and that “we have to be the face of change at NIH.” She noted the great achievements in treatments for sickle cell disease, but emphasized that this is not yet good enough. She said her slogan is the we are “not finished until all people live long and healthy lives.”
Session 1: AI & Its Potential Role in Rare Diseases
Dr. Bertagnolli’s remarks were followed by Session 1: Artificial Intelligence (AI) and Its Potential Role in Rare Diseases. This session began with an introduction to AI and an outline of how it can be used to benefit rare disease patients. Attendees then learned about multiple case studies exemplifying the role AI has played in reducing the diagnostic odyssey, identifying rare disease patients for clinical trials, and building tools to repurpose drugs. Presentations were followed by a moderated Q&A with the panelists.
The moderator of Session 1 was Christine Cutillo, MMCi, Health Data Scientist for AI Ethics, Office of Data Science Strategy, Office of the Director, NIH. The panelists who gave brief presentations and then participated in a panel discussion were Kimberly Moran, PhD, MBA, Head, US Rare Diseases, UBC, Inc.; Manisha Balwani, MD, Professor and Chief, Division of Medical Genetics and Genomics, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai; and Ewy A. Mathé, PhD, Director, Informatics Core, Division of Preclinical Innovation, NCATS, NIH.
Rare Disease Story #3: Hesperos Human-on-a-Chip Technology
The panel discussion was followed by Rare Disease Story #3 which focused on the use of chip technology as experimental models for rare diseases, for which there are very few animal models. This story was told by James Hickman, PhD, Professor, Chemistry, University of Central Florida; Co-Founder and Chief Scientific Officer, Hesperos, Inc., the original Human-on-a-Chip company. Dr. Hickman emphasized the wide utility of chip models for the study of rare diseases and the fact that the models involve no killing of cells.
Rare Disease Story #4: Science & Serendipity: Bachmann-Bupp Syndrome
Next was the riveting Rare Disease Story #4, in which researchers from Michigan State University described the characterization and treatment of a newly identified rare disease known as Bachmann-Bupp syndrome, named after the researchers. The presenters were the researchers themselves: André S. Bachmann, PhD, Professor and Associate Chair for Research, Scientific Director of the International Center for Polyamine Disorders, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University; and Caleb P. Bupp, MD, Division Chief, Medical Genetics and Genomics, Corewell Health and Helen DeVos Children’s Hospital, Assistant Professor, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University; Clinical Director, International Center for Polyamine Disorders.
The story began when Dr. Bupp’s had a case of a 3-year-old girl whose symptoms were complete hair loss, an enlarged head, low muscle tone, and developmental delays. The girl’s hair had fallen out in chunks shortly after birth. With assiduous research and genetic testing, Dr. Bupp established that the girl had a disease caused by a point mutation in the gene ODC1 which codes for the enzyme ornithine decarboxylase 1 which is involved in so-called polyamine pathways. The mutation causes 3′ end mutations of the ODC1 gene which produces C-terminally truncated variants of ODC, a pyridoxal 5′-phosphate-dependent enzyme. This change prevents ubiquitin-independent proteasomal degradation and leads to cellular accumulation of ODC. This leads, in turn, to an increased conversion of ornithine to putrescine, causing an accumulation of putrescine. So, if the ODC protein is not properly degraded leading to an accumulation of ODC and later putrescine, it causes many gain-of-function mutations. This leads to a wide variety of symptoms which is why misdiagnosis is often a reality. Penetrance of the pathogenic variants for the ODC1 gene is believed to be 100%.
Dr. Bupp knew little about this gene or the polyamine pathways when he discovered the mutation, but he subsequently just happened to attend a grand rounds during which Dr. Bachmann described polyamine pathways and his 30 years of work on ODC. Dr. Bupp and Dr. Bachmann quickly joined forces and expertises to pursue disease elucidation and possible treatment with a known inhibitor of ODC intended to block the disease-causing buildup of ornithine and putrescine.
An exploratory treatment currently being studied by the FDA is the use of difluoromethylornithine (DFMO). DFMO is an irreversible inhibitor of the ODC enzyme. A case study was created and, with approval from the FDA, a young patient began treatment at 4 years and 8 months old. During the first three months the patient received a 500 mg/m2 dose twice a day orally. After the first three months a physical examination showed increased eyebrow and scalp hair growth with improved muscle tone. After the examination, the patient’s dosage was increased to a 750 mg/m2 dose twice a day for another three months. This then was increased to a 1000 mg/m2 dose twice a day. Since the beginning of the treatment, the patient has fully grown hair on the scalp, eyebrows, and eyelashes. No side effects have been observed. Also, post treatment of the use of DFMO has shown that myelination of white matter in the brain has increased. This has shown that the use of the drug twice a day has improved neurological function.
This progress is very hopeful news for patients with Bachmann-Bupp syndrome, which is extremely rare with just 16 known patients in the entire world today. It is also a rich example of how basic science, coupled with keen insight and dogged determination, can lay the groundwork for tremendous progress in the diagnosis and treatment of rare diseases.
Luncheon Break
During the lunch break, attendees visited the over 100 posters and exhibits, attended a rare disease art show (“Beyond the Diagnosis”) which depicts the very human side of rare diseases, especially for children, viewed films on rare diseases, and networked with other attendees.
Rare Disease Story #5: Patient Becomes Successful Film Director
After lunch, the audience heard a soaring story of triumph over rare disease by a sufferer and also a great success. Young Ashley Eakin related how she had struggled all her life with a rare disease that affects under 200 people in the world. Ashley said she has endured 28 surgeries and had 2 bouts of ovarian cancer while somehow still managing to pursue her life-long love of story-telling and ultimately becoming a film director. A true inspiration.
Rare Disease Story #6: Wolfram Syndrome
Rare Disease Story #6 focused on Wolfram syndrome, a rare genetic disorder resulting from the inheritance of two mutated copies of the WFS1 or CISD2 gene. This syndrome is characterized by juvenile-onset diabetes, optic nerve atrophy, and neurodegeneration, and affects approximately 1 in 500,000 individuals. The story was presented by physician/researcher Fumihiko Urano, MD, PhD, Samuel E. Schechter Professor of Medicine, Director of Wolfram Syndrome and Related Disorders Clinic, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine in St. Louis. Dr. Urano discussed diagnosis, clinical protocols, and advances in gene editing, regenerative, and molecular targeted therapies. Information on Wolfram syndrome work by Dr. Urano’s group at Washington University can be found here. Dr. Urano noted that an estimated 3% of Ashkenazi Jews are carriers of this rare disease. There is no known direct treatment.
Current treatment efforts focus on managing the complications of Wolfram syndrome, such as diabetes mellitus and diabetes insipidus. However, a number of symptoms can be managed to improve quality of life. These include: insulin for diabetes alongside other medications for this. Also included are desmopressin to treat diabetes insipidus, antibiotics for UTIs, hearing aids of cochlear implants for hearing loss, and supportive aids for visual loss such as magnifying glasses.
New treatment advances include research evaluating endoplasmic reticulum (ER) calcium stabilizers and repurposed drugs/small molecules to reduce ER stress and reduce apoptosis, thus slowing progression of Wolfram syndrome. A three-tiered approach toward the treatment of Wolfram syndrome includes stopping disease progression, protecting and regrowing remaining tissue, and replacing and repairing pathogenic genes.
Rare Disease Story #7: Gene Therapy Development in Industry
Meredith Schultz, MD, SVP, Head of Clinical Development and Medical Affairs, Taysha Gene Therapies, discussed gene therapy development in industry—past, present, and the future. Dr. Schultz is highly experienced in gene therapy, having worked on gene therapy for spinal muscular atrophy as a clinician at the University of Wisconsin and now working on a gene therapy for Rett syndrome in industry at Taysha Gene Therapies. Taysha is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).
Rare Disease Story #8: Vamorolone: How a Public-Private Partnership Succeeded in Bringing a Rare Disease Drug to Market
Dominique C. Pichard, MD, Director, DRDRI, NCATS, NIH, moderated a discussion of the journey of the drug vamorolone for Duchenne muscular dystrophy (DMD) from research to market in a public-private partnership involving ReveraGen BioPharma Inc., a venture philanthropy company. Vamorolone is the first FDA-approved drug for DMD and it is based on the observed anti-inflammatory benefits of corticosteroids (e.g., prednisone) for the disease, but without the serious side effects associated with those drugs. Vamorolone has achieved an improved safety profile by removal of a single oxygen moiety from the corticosteroid backbone (at the 11β position). This differentiates vamorolone from all other members of the corticosteroid class. Speakers in this session included Eric P. Hoffman, PhD, Professor of Pharmaceutical Sciences, Binghamton University, State University of New York; CEO, ReveraGen BioPharma, Inc., and Sharon Hesterlee, PhD, Chief Research Officer, Muscular Dystrophy Association.
Session 2: Recent Approvals and Advancements in Gene Therapy
This session began with a brief introduction and overview of genetic therapies by moderator: Philip John Brooks, Ph.D., Deputy Director, DRDRI, NCATS, NIH. This was followed by remarks by Nicole Verdun, MD, Super Office Director, Office of Therapeutic Products, Center for Biologics Evaluation and Research (CBER), FDA, who spoke on new initiatives and recent guidances related to gene therapies. Next, researchers described recent approvals for genetic therapies for three rare diseases, highlighting potential clinical impact, relevance for similar diseases, remaining challenges, and concerns, as well as patient perspectives.
Gene Therapy for Patients with Dystrophic Epidermolysis Bullosa
M. Peter Marinkovich, MD, Associate Professor, Department of Dermatology, Stanford Medicine described the development of an approved treatment for the devastating blistering disease known as dystrophic epidermolysis bullosa. The disease is caused by mutations within the human COL7A1 gene encoding the protein type VII collagen. Collagen VII is a very large molecule that dimerizes to form a semicircular looping structure: the anchoring fibril. Anchoring fibrils are thought to form a structural link between the epidermal basement membrane and the fibrillar collagens in the upper dermis.
In May 2023, the FDA approved Vyjuvek (beremagene geperpavec) for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. The approval of Vyjuvek was granted to Krystal Biotech, Inc. Beremagene geperpavec is the first approved gene therapy to use herpes-simplex virus type 1 as a vector. Beremagene geperpavec is a genetically modified (engineered in a laboratory) herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds.
The results have been very encouraging as the terrible blistering of the disease is significantly reduced and the lives of patients have been dramatically improved. At the end of his talk, Dr. Marinkovich played a video of a young boy who had received the gene therapy treatment and he movingly described how much better his life was as a result.
Gene Therapy for Patients with Cerebral Adrenoleukodystrophy (CALD)
Florian S. Eichler, MD, Director, Center for Rare Neurological Diseases, Massachusetts General Hospital; Professor, Neurology, Harvard Medical School, described the recent approval of a helpful gene therapy for cerebral adrenoleukodystrophy (CALD). The FDA-approved therapy is named Skysona (elivaldogene autotemcell). Skysona is manufactured by bluebird bio Inc., and is the first and only approved gene therapy that slows the progression of neurologic dysfunction in boys with early, active CALD.
Adrenoleukodystrophy (ALD) is a rare, X-linked, metabolic disorder caused by a mutation in the ABCD1 gene which results in the toxic buildup of very long-chain fatty acids (VLCFAs) in the brain and spinal cord. CALD is the most severe and neurodegenerative form of this condition.
The accumulation of VLCFA in the adrenal cortex and white matter of the brain and spinal cord leads to the progressive destruction of myelin, the protective sheath of the nerve cells in the brain that are responsible for thinking and muscle control. Without myelin, these nerves can no longer relay information to and from the brain.
Once this occurs, this damage can be seen on magnetic resonance imaging (MRI) of the brain, which is when the cerebral form of adrenoleukodystrophy (CALD) is diagnosed. Skysona may be recommended if this damage is determined to be early (based on a lesser degree of the damage on MRI) and if cerebral disease is active (based on presence of contrast enhancement on MRI that indicates this damage is ongoing).
Skysona is made specifically for each patient, using the patient’s own blood stem cells, and adds functional copies of the ABCD1 gene to the patient’s cells. This may help the body to break down the VLCFAs to slow the progression of damage to the brain and slow the decline in neurologic function. Skysona is a one-time gene therapy to treat boys with early, active CALD.
Two Gene Therapies for Sickle Cell Disease
Alexis K. Leonard, MD, Assistant Member, Department of Hematology, St. Jude Children’s Research Hospital, described two gene therapy approaches approved by the FDA in December 2023 for sickle cell disease.
On December 8, 2023, the FDA approved two milestone treatments, casgevy and lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.
Sickle cell disease is a group of inherited blood disorders affecting approximately 100,000 people in the U.S. It is most common in African Americans and, while less prevalent, also affects Hispanic Americans. The primary problem in sickle cell disease is a mutation in hemoglobin, a protein found in red blood cells that delivers oxygen to the body’s tissues. This mutation causes red blood cells to develop a crescent or “sickle” shape. These sickled red blood cells restrict the flow in blood vessels and limit oxygen delivery to the body’s tissues, leading to severe pain and organ damage called vaso-occlusive events (VOEs) or vaso-occlusive crises (VOCs). The recurrence of these events or crises can lead to life-threatening disabilities and/or early death.
Casgevy, a cell-based gene therapy from Vertex Therapeutics, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. Patients’ hematopoietic (blood) stem cells are modified by genome editing using CRISPR/Cas9 technology.
CRISPR/Cas9 can be directed to cut DNA in targeted areas, enabling the ability to accurately edit (remove, add, or replace) DNA where it was cut. The modified blood stem cells are transplanted back into the patient where they engraft (attach and multiply) within the bone marrow and increase the production of fetal hemoglobin (HbF), a type of hemoglobin that facilitates oxygen delivery. In patients with sickle cell disease, increased levels of HbF prevent the sickling of red blood cells.
Lyfgenia, marketed by bluebird bio, Inc., is also a cell-based gene therapy. Lyfgenia uses a lentiviral vector (gene delivery vehicle) for genetic modification and is approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events. With lyfgenia, the patient’s blood stem cells are genetically modified to produce HbAT87Q, a gene-therapy derived hemoglobin that functions similarly to hemoglobin A, which is the normal adult hemoglobin produced in persons not affected by sickle cell disease. Red blood cells containing HbAT87Q have a lower risk of sickling and occluding blood flow. These modified stem cells are then delivered to the patient.
At the end of this presentation, Dr. Leonard played a video of a young man describing how the sickle cell gene therapy had radically changed his life and eliminated his pain. “My life is completely different. I feel amazing,” he said.
Meeting Closes
Dr. Rutter then came back to the podium and closed the meeting by hailing its success and saying she looked forward to seeing everyone again next year.
by Michael D. O’Neill, Editor & Publisher, BioQuick News
